Homology modeling analysis of the effect of α and β subunits of the interaction of Shiga toxin with Interferon gamma, Prostaglandin G/H synthase 2, and Sodium/ glucose cotransporter 1 proteins as a step for cancer suppression

Document Type : Research Paper

Author

1Department of Microbiology, Falavarjan Branch, Islamic Azad University, Isfahan, Iran

Abstract

Background and Objectives: With of bioinformatics technology advancement, new methods of cancer treatment, such as the use of bacterial toxins, can now be explored more rapidly. In the present bioinformatics study, the probable attachment of Shiga toxin subunits to Interferon gamma (IFNG), Prostaglandin G/H synthase 2 (PTGS2), and Sodium/ glucose cotransporter 1 (SGLT1) was investigated to take a step towards cancer suppression.
Methods: The gene sequences were extracted from NCBI database. SWISS-MODE and jmol databases were used to detect the sequence and model the three-dimensional structure of proteins, respectively. The effect of StxA and StxB on IFNG, PTGS2 and SGLT1 proteins was evaluated with ZDOCK data base.
Results: Three-dimensional structure of proteins showed that the StxA protein was not a monomer, and that StxB had flat structures that bound it to the cell surface. Alpha helices and beta sheets are present in IFNG, and this monomeric protein lacks a symmetric tertiary structure. PTGS2 has a large complex structure consisting of several alpha helices and a beta sheet. In SGLT1, which is a transmembrane protein, only alpha helices were seen. There is a significant interaction between Shiga toxin protein and all three proteins IFNG, PTGS2 and SGLT1 by the method of molecular docking.
Conclusion: Findings of this study provide a new dedication for laboratory studies of the effect of Shiga toxin to evaluate its ability to stimulate the immune system, reduce tumor growth and treat cancer according to its ability to attach to the proteins which are effective in these processes.

Keywords

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-86. Link
  2. Raguz, S., Yagüe, E., 2008. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer. 99(3): 387. Link
  3. Kaur, S., Kaur, S., 2015. Bacteriocins as potential anticancer agents. Front Pharmacol 6, 272. Link
  4. Zitvogel L., Daillere R., Roberti MP., Routy B., Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017; 15(8): 465. Link
  5. Sai L, Xiaoping X, Xin Z, Longjiang L, Qianmimng C, Jing L. Tumor‑targeting bacterial therapy: A potential treatment for oral cancer. Rev Onc Let 2014; 8(6): 2359-2366. Link
  6. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001; 81: 93-124. Link
  7. O’brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, Sandvig K, Lindberg AA, Keusch GT. Pathogenesis of Shigellosis Shiga toxin. Berlin: Springer: 1992. P. 65-94. Link
  8. Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med 2018; 7(9): 4509-16. Link
  9. Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int Jo Cancer 2018; 142(8): 1712-22. Link
  10. Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 2013; 35(2): 229-244. Link
  11. Bakhle YS. Cox-2 and cancer: a new approach to an old problem. British J Phamacol 2001; 134: 1137-50. Link
  12. Dannenberg AJ, Altork NK, Boyle JO, Dang C, Howe LR, weksler BB, et al. 2001. Cyclooxygense 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2: 544-51. Link
  13. Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E, et al. Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol Res 2017; 5: 695–709. Link
  14. Zelenay S, Van Der Veen A G, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 2015; 162: 1257–1270. Link
  15. Singh B, Lucci A. Role of cycloxygenase-2 in breast cancer. Surg Res 2002; 108: 173-79.
  16. Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res 2010; 38(suppl_2): W445-9. Link
  17. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res 2011; 17(19): 6118-24. Link
  18. Yoshida T, Sugiyama T, Koide N, Mori I, Yokochi T. Human microvascular endothelial cells resist Shiga toxins by IFN-γ treatment in vitro. Microbiol 2003; 149(9): 2609-14. Link
  19. Barczak K, Palczewska-Komsa M, Nowicka A, Chlubek D, Buczkowska-Radlińska J. Analysis of the activity and expression of cyclooxygenases COX1 and COX2 in THP-1 monocytes and macrophages cultured with biodentine TM silicate cement. Int J Mol Sci 2020; 21(6): 2237. Link
  20. Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci 2015; 112(30): E4111-E9. Link
  21. Obara K, Shirakami Y, Maruta A, Ideta T, Miyazaki T, Kochi T, et al. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget 2017; 8(35): 58353. Link
  22. Kato J, Shirakami Y, Ohnishi M, Mizutani T, Kubota M, Sakai H, et al. Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. Oncol Rep 2019; 42(6): 2797-805. Link
  23. Oloomi M, Bouzari S Arshadi M. N-terminus leader sequence of shiga toxin
    (Stx) 1 is essential for production of active recombinant protein in coli. Protein Pept Lett 2018; 13(5): 509-512. Link
  24. Gariépy J. The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol 2001; 39(1-2): 99-106. Link
  25. Foster GH, Armstrong CS, Sakiri R, Tesh VL. Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect Immun 2000; 68(9): 5183-9. Link
  26. Engedal N, Skotland T, Torgersen ML, Sandvig K. Shiga toxin and its use in targeted cancer therapy and imaging. Microbial Biotechnol 2011; 4(1): 32-46. Link
Medical Journal of Mashhad university of Medical Sciences
Volume 65, Issue 2
May and June 2022
Pages 666-679

Files

Share

How to cite

Statistics